How Sermorelin works
An experimental short-acting peptide that triggers growth hormone release, with limited evidence of adult benefits.
Also called: Sermorelin acetate, Geref, GHRH(1-29)-NH2, GRF(1-29)-NH2, Groliberin.
GHRH analogues · Growth hormone-releasing hormone receptor agonist.
It copies the first 29 amino acids of a brain hormone called GHRH. It tells the pituitary to release growth hormone, which can raise IGF-I. A working pituitary is needed; a higher hormone level does not guarantee better health.
- GHRH receptor: Triggers growth hormone release from pituitary cells.
- GH–IGF-I pathway: Released GH can increase IGF-I production and growth signals in other tissues.
Half-life: Short and method-dependent: 4.3 ± 1.4 minutes after IV infusion; an old Irish diagnostic label reports 6–7 minutes IV.
Related to Sermorelin
- CJC-1295 without DAC: A peptide intended to trigger growth hormone release, with no human dosing study found.
- Tesamorelin: A peptide approved for deep abdominal fat in adults with HIV lipodystrophy.
- CJC-1295 with DAC: An experimental long-acting peptide that triggers growth hormone release, with no proven muscle or recovery benefit.
- Tirzepatide: A weekly GIP/GLP-1 injection with strong diabetes and weight-loss evidence and common stomach side effects.
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- Ipamorelin: An experimental peptide that triggers growth hormone release.
Sources
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act, FDA · FDA · 2026
- Compounding and the FDA: Questions and Answers, FDA · FDA · 2026
- Search Results - (emc), 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks, 2025
- October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee, FDA · 2024
- Xcel Research LLC - 694608 - 12/10/2024, 2024
- Innoveix Pharmaceuticals Inc - 624782 - 01/26/2022, 2022
- Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness, 2013
- Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline., Molitch ME et al. · The Journal of clinical endocrinology and metabolism · 2011
- Geref (Seristim), 2005
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.